Olaparib AZD-2281 CAS 763113-22-0 Ubunyulu ≥99.0% API Factory
Ukucoceka okuphezulu, iMveliso yoRhwebo
I-Olaparib kunye nabaPhakathi abaNxulumeneyo:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
I-2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl)piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Igama leMchiza | Olaparib |
| Izithethantonye | I-AZD-2281;KU0059436;Lynparza;4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-enye;1-(Cyclopropylcarbonyl) -4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin |
| Inombolo yeCAS | 763113-22-0 |
| Inombolo yeCAT | RF-API103 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C24H23FN4O3 |
| Ubunzima beMolekyuli | 434.46 |
| Ukunyibilika | Inyibilika kwi-DMSO |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Mhlophe ukuya kwi-Off-White Powder |
| Ukuchongwa ngu-1H NMR | Ukuthobela isakhiwo |
| I-LC-MS | Ukuthobela isakhiwo |
| Ubunyulu / Indlela yokuHlalutya | ≥99.0% (nge-LC-MS) |
| Ukufuma (KF) | ≤0.50% |
| Ukungacoceki Okukodwa | ≤0.50% |
| Ukungcola ngokupheleleyo | ≤1.0% |
| Iintsimbi ezinzima (njenge Pb) | ≤20ppm |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | API;I-PARP Inhibitor |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, Igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma.
I-Olaparib (i-CAS: 763113-22-0), i-PARP-inhibitor enamandla kakhulu kwaye ekhethiweyo.NgoDisemba 19, 2014, i-FDA ivume inoveli echasene nomhlaza ichiza i-Olaparib (i-Lynparza) ye-monotherapy kwizigulana ezinomhlaza we-ovarian ophezulu oye wafumana ubuncinane imijikelo ye-3 ye-chemotherapy okanye izigulane ezikrokrelekayo zokuguqulwa kwe-BRCA.Kwangaxeshanye, i-FDA yavuma ubungakanani kunye nokuhlelwa kweekhithi zokuxilonga ukuze kufunyanwe utshintsho kwi-BRCA1 kunye ne-BRCA2, i-BRCAanalysis CDx.I-Olaparib yeyokuqala i-PARP inhibitor ichiza evunywe yi-FDA.Ngomhla we-2 kaFebruwari, i-2015, i-European Union Food and Drug Administration (EMA) nayo yavuma ukuba i-Olaparib ingene kwiimarike kumazwe angama-28 e-European Union kuquka i-Iceland, iLiechtenstein neNorway.Kodwa izibonakaliso ze-EMA kunye ne-FDA evunyiweyo zahluke kancinane;Eyangaphambili yeyeemeko zokuguqulwa kofuzo lwe-BRCA, kunye nonyango lolondolozo lwezigulana ezinomhlaza we-epithelial ovarian othe wafumana ngaphambili amachiza echemotherapy aneplatinam kwaye abonisa impendulo kwaye axhomekeke ekuphindekeni.
